Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
This artificial RNA ligase has higher thermostability than natural RNA ligase
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
There is a fast resurgence in the transplant activities post COVID
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
Themis will market this drug with the brand name REMITHEM.
Subscribe To Our Newsletter & Stay Updated
